StockMarketWire.com - Edison has issued a research update on Angle.

It says: "Angle has announced results from a metastatic breast cancer research study carried out by its KOL partner University of Southern California (USC) Norris Comprehensive Cancer Center. Headline data potentially prove that circulating cancer cells (CTCs) captured using Parsortix have the same biology compared to invasive tissue biopsy and can be used to guide the treatment. While this will have to be replicated in larger-scale trials, it represents a potential third clinical application, in which Parsortix can establish a new standard of care.

"Angle will now focus on implementing a clinical trial in partnership with USC and other centres. When there is more clarity about commercialisation in terms of timelines and positioning, we will review our financial forecasts and the assumptions underlying our DCF-based valuation, which is unchanged at GBP95m or 161p/share for now."

The full report is available at: www.edisoninvestmentresearch.com


At 1:06pm: [LON:AGL] Angle PLC share price was -1p at 69.5p



Story provided by StockMarketWire.com